Rankings · Stocks
Best-performing Stocks
Compare investable companies across valuation, growth, quality, income and returns.
Latest complete snapshotSep 1, 2026
Snapshot observation
SharonAI Holdings, Inc. Class A Common Stock has the highest qualifying performance reading. The eligible median is 15.67 across 3398 instruments.
Ranks 11–20 comparison
1Y total return
Bars follow the current ranking, filter and page.
11
0O5CAT & S Austria Technologie & Systemtechnik AG+683.18%
+683.18%
12
PRAXPraxis Precision Medicines Inc+669.21%
+669.21%
13
FBRXForte Biosciences Inc+599.91%
+599.91%
14
SLSSellas Life Sciences Group Inc+594.79%
+594.79%
15
LITELumentum Holdings Inc+588.77%
+588.77%
16
IMMXImmix Biopharma Inc+531.98%
+531.98%
17
ORKAOruka Therapeutics, Inc.+525.81%
+525.81%
18
MRNAModerna Inc+482.57%
+482.57%
19
WDCWestern Digital Corporation+462.32%
+462.32%
20
SYRESpyre Therapeutics Inc.+441.72%
+441.72%
| Rank | Instrument | Classification | Region | Market cap | 1M | YTD | 1Y |
|---|---|---|---|---|---|---|---|
| 11 | 0O5CAT & S Austria Technologie & Systemtechnik AG | Stock | Europe | $2.3B | +17.84% | +381.62% | +683.18% |
| 12 | PRAXPraxis Precision Medicines Inc | Stock | North America | $9.6B | +13.80% | +18.85% | +669.21% |
| 13 | FBRXForte Biosciences Inc | Stock | North America | $1.6B | +0.51% | +182.32% | +599.91% |
| 14 | SLSSellas Life Sciences Group Inc | Stock | North America | $2.7B | +33.27% | +253.85% | +594.79% |
| 15 | LITELumentum Holdings Inc | Stock | North America | $84.2B | +28.13% | +148.18% | +588.77% |
| 16 | IMMXImmix Biopharma Inc | Stock | North America | $1B | +68.63% | +168.26% | +531.98% |
| 17 | ORKAOruka Therapeutics, Inc. | Stock | North America | $6B | -4.03% | +205.58% | +525.81% |
| 18 | MRNAModerna Inc | Stock | North America | $55.1B | +156.00% | +375.89% | +482.57% |
| 19 | WDCWestern Digital Corporation | Stock | North America | $165.7B | -17.31% | +161.73% | +462.32% |
| 20 | SYRESpyre Therapeutics Inc. | Stock | North America | $8B | -9.15% | +172.68% | +441.72% |
Informational only. Rankings are not investment advice, a recommendation, or a prediction of future performance.